Category Archives: Drug Development

Sixth Annual Chair Summit Begins This Week

This week a Master Class for Neuroscience Development called the Chair Summit takes place in Tampa, FL (Sept 26-28, 2013). In the early days of medical training in Kos, students, trainees and medical colleagues would gather to discuss their cases … Continue reading

Posted in Addiction, ADHD, Antipsychotic medication, Anxiety Disorders, Biomarker, Bipolar Disorder, Cardiovascular Risk Factors, Chronic Pain, CME, Dementia, Depression, Diabetes, Diagnosis, Digital medicine, Drug Development, Drugs, DSM-5, Early intervention, Education, Food, Genetics, Guideline, Imaging, Maintenance of Certification, Measurement-based care, Medical Education, Mood, MRI, Multiple sclerosis, Negative symptoms, Neuroscience, Obesity, Opioids, PET, Practice guideline, Psychosis, PTSD, Research, Schizophrenia, Smoking cessation, Social media, Stroke, Substance abuse, Transcranial magnetic stimulation, Vascular dementia | Comments Off on Sixth Annual Chair Summit Begins This Week

Experts Convene to Focus on Medication-Development Slowdown

This month the American Psychiatric Association assembled experts from academia, the pharmaceutical industry, venture-capital firms, advocacy groups, and government agencies to discuss the serious decline in the number of medications being developed to treat psychiatric illnesses. The summit was moderated … Continue reading

Posted in Drug Development, Research | Comments Off on Experts Convene to Focus on Medication-Development Slowdown